Screener
Mirum Pharmaceuticals, Inc. MIRM Other income, net (Note 6)
Other income, net (Note 6) at other companies
Other financials
Where this comes from
Reported directly by Mirum Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The source filing: Mirum Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001759425-26-000045
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Other income (expense): | ||||
| Interest income | 3,851 | 3,033 | 7,252 | 6,056 |
| Interest expense | (2,618) | (3,589) | (6,234) | (7,185) |
| Other (expense) income, net | (24,234) | 86 | (24,234) | 2,194 |
| Net loss before provision for income taxes | (65,538) | (5,459) | (855,218) | (19,107) |
| Provision for income taxes | 1,689 | 402 | 2,164 | 1,431 |
| Net loss | $(67,227) | $(5,861) | $(857,382) | $(20,538) |
| Net loss per share, basic and diluted | $(1.06) | $(0.12) | $(14.03) | $(0.42) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Mirum Pharmaceuticals, Inc.'s other income, net (note 6)?
- Mirum Pharmaceuticals, Inc. (MIRM) reported other income, net (note 6) of -$24.23M in Q2 2026.
- How has Mirum Pharmaceuticals, Inc.'s other income, net (note 6) changed year-over-year?
- Mirum Pharmaceuticals, Inc.'s other income, net (note 6) decreased by 28279.1% year-over-year, from $86K to -$24.23M.
- What is the long-term trend for Mirum Pharmaceuticals, Inc.'s other income, net (note 6)?
- Over 3 years (2021 to 2025), Mirum Pharmaceuticals, Inc.'s other income, net (note 6) has grown at a 64.5% compound annual growth rate (CAGR), from -$582K to $2.59M.
- What does other income, net (note 6) mean?
- This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.
Ask your AI about Mirum Pharmaceuticals, Inc.'s other income, net (note 6).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude